Journal List > J Korean Neuropsychiatr Assoc > v.52(5) > 1017641

Choi, Na, Lee, Oh, Hahm, and Jung: Informed Consent in Psychiatry

Abstract

Informed consent is the procedure that respects the autonomy of patients ; doctors protect patients' choices and rights through informed consent. Competence and voluntariness are prerequisite for the informed consent. In recent years, the necessity of informed consent from the Psychiatric department has been raised. Regarding informed consent from the Psychiatric department, there is a need to consider from two perspectives : respect for the patient's decision-making ability and the psychiatrist's legal self-protection. In competence and voluntariness, psychiatric patients were excluded due to lack of decision-making ability and willingness. However, not all psychiatric patients were able to perform the given task. Therefore, informed consent is needed in the point of view regarding the decision-making ability of psychiatric patients. Psychotropic medications, particularly antipsychotics, can cause several side effects, including extrapyramidal syndrome and metabolic syndrome. Therefore, preannouncement of these patients for these side effects is needed. However, when the informed consent is only applied to psychiatric hospitals, it may increase prejudices and misconceptions about psychiatric medications and treatment. Therefore, the informed consent should first be considered carefully and thoughtfully.

Notes

The authors have no financial conflicts of interest.

References

1. Hong SY. The standard to measure patient's decision-making competence in informed consent. Korean J Med Ethics. 2005; 8:44–59.
2. Dalla-Vorgia P, Lascaratos J, Skiadas P, Garanis-Papadatos T. Is consent in medicine a concept only of modern times? J Med Ethics. 2001; 27:59–61.
3. Choi Byoung-in. Introduction to biomedical research integrity and its systems. GCO Science;2009. p. 110–111.
4. Pellegrino E. For the patient's good. Oxford University Press;1988. p. 149.
5. Brody B. Life and death decision making. Oxford University Press;1988. p. 101.
6. Medical Law Enforcement Rules. 2013. 17. 04.
7. 79do1387 judgement. Supreme Court of Korea;1980. 24. 09.
8. Beauchamp T. Childress J, editor. Principles of biomedical ethics. Oxford University Press;2001. p. 72–74.
9. Dochin A. Understanding autonomy relationally: toward a reconfiguration of bioethics principles. J Med Philos. 2001; 26:368–374.
10. mental health law, law no.11005. 2011. 04. 08.
11. Criminal Law no.10259. 2010. 16. 10.
12. Grisso T, Appelbaum PS. Mentally ill and non-mentally ill patients' abilities to understand informed consent disclosures for medication. Law Hum Behav. 1991; 15:377–388.
13. Kitamura F, Atsuko T, Kazumi T, Makoto T, Ikuko K, Shuuichi M, et al. Method for assessment of competency to consent in the mentally ill: Rationale, development, and comparison with the medically ill. Int J Law Psychiatry. 1998; 21:223–244.
14. A declaration on the promotion of patient's rights in Europe. In : European consultation on the rights of patients; WHO;1994.
15. Simon . Clinical psychiatry and law. Washington DC: American psychiatry press;1987.
16. The National Mental Health Commission business report. Ministry of Health & Welfare;2007.
17. Chung IW, Shin CJ, Son JW, Suh TW. A Study on the Judgement for Hospitalization of the Mental Health Judgement Boards. J Korean Neuropsychiatr Assoc. 2003; 42:520–527.
18. Hong JP. Mental health care institution ? 2013; 28. 02. 53(2):
19. Seoul Central District Court 90gahab45545. 1992. 13. 03.
20. Korean Neuropsychiatric Association. Textbook of neuropsychiatry. 2nd ed. Seoul: Joonang;2005. p. 650.
21. Liperoti R, Pedone C, Lapane KL. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med. 2005; 165:2677–2682.
22. Recupero PR, Rainey SE. Managing risk when considering the use of atypical antipsychotics for elderly patients with dementia-related psychosis. J Psychiatr Pract. 2007; 13:143–152.
23. Quality Measure/Indicator Report. Psychotropic drug use - July/September 2010. CMS.gov [homepage on the Internet]. Baltimore: Minimum Data Set;Available from: http://www.cms.gov/Research-Statistics-Data-and-Systems/Computer-Data-and-Systems/MDSPubQIandResRep/qmreport.html.
24. important drug warning and new information. FDA.gov [homepage on the Internet]. New Hampshire: US Food and Drug Administration;2005. Available from: http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM153074.pdf.
25. 2004 Safety Alert:Zyprexa(olanzapine). FDA.gov [homepage on the Internet]. New Hampshire: US Food and Drug Administration;Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm166542.htm.
26. Lee Duckhwan. Medical treatment and Law. Seoul: Hyunmoon;2006. p. 119.
27. Gutheil Appelbaum. Clinical handbook of psychiatry and the law. McGraw-hill book company;1982. p. 160.
28. Seoul High Court 2010na24017. 2012. 22. 03.
29. David cohen, David Jacobs. A Model Consent Form for Psychiatric Drug Treatment. Journal of Humanistic Psychology. 2000; 40:59–64.
30. Sfdph.org [homepage on the Internet]. San Francisco: City and county of San Francisco Department of Public health;Available from: http://www.sfdph.org/dph/files/CBHSPolProcMnl/MedicationConsentForm-062004rev.pdf.
TOOLS
Similar articles